Sp947
MEDICAL MANAGEMENT OF GASTROPARESIS
Date
May 20, 2024
Presenter
Mayo Clinic College of Medicine
Tracks
Related Products
THE CLINICAL VALUE OF BIOMARKER-BASED APPROACHES FOR THE EVALUATION AND MANAGEMENT OF IRRITABLE BOWEL SYNDROME: PRICE VS. PRECISION
DDW attendees will have the opportunity to learn about recent developments in biomarker-discovery for FGID/DGBI and Neurogastroenterology…
MACHINE-LEARNING DRIVEN, FULL PHENOTYPE MODEL AND SURROGATE POLYGENIC RISK SCORE MODEL FOR APPETITE PREDICT RESPONSE TO GLP-1 RECEPTOR AGONIST IN PATIENTS WITH OBESITY
Background: Transoral outlet reduction endoscopy (TORe) has been shown to be effective in managing weight regain after Roux-en-Y gastric bypass (RYGB), as has the glucagon-like peptide-1 agonist, liraglutide. However, the effect of adjunctive liraglutide after TORe has yet to be assessed…
When to Think of Bile Acid Diarrhea
LIVE STREAM SESSION Bile acid diarrhea is an under-recognized disorder which is often overlooked. It can be treated with well-established medications and new approaches are available…
INCREASED NUMBERS OF SINGLE NUCLEOTIDE VARIANTS IN GENES RELATED TO BILE ACID KINETICS ARE ASSOCIATED WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME: A WHOLE EXOME SEQUENCING STUDY OF 526 PATIENTS AND 2950 CONTROLS
BACKGROUND: Irritable bowel syndrome (IBS) is a common disorder with complex pathophysiological mechanisms. Prior studies suggest that 25-50% of patients with diarrhea-predominant IBS (IBS-D) have evidence of bile acid (BA) diarrhea (BAD)…
